ive immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.
The OVA1 Test is an aid to further assess the likelihood that malignancy is present when the physician's independent clinical and radiological evaluation does not indicate malignancy. The test should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 Test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.
Quest Diagnostics, which is a long-time investor in research and development of the OVA1 technology, has exclusive rights to offer the test to the clinical reference laboratory market in the U.S. for three years.
About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.
Contact:
Vermillion:
Jill Totenberg
The Totenberg Group
Tel: 212 994 7363
'/>"/>
SOURCE Vermillion, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock2.
Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease3.
Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq4.
Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York5.
Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests6.
Vermillion Receives NASDAQ Notice of Non-Compliance7.
Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk8.
Vermillion Announces Effectiveness of Reverse Stock Split9.
Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones10.
Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization11.
Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease